Feedback to FDA: Human gene therapy for neurodegenerative diseases: draft guidance for industry
A cross collaboration of members participated in a series of meetings to review FDA Human gene therapy for neurodegenerative diseases: draft guidance for industry which was published for public consultation January 2021.
A summary document detailing consolidated feedback and suggested recommendations that represented the views of member companies was submitted to the FDA in April 2021 for consideration prior to finalizing.
I don't have access to this document
Make a selection below and submit your request. We will get back to you ASAP.
My company would like to become a member
If you're not sure if your company is a member of this Phorum, or if you would like to enquire on behalf of your company about becoming a member, please see our membership page.